These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22901132)

  • 21. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
    Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
    Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
    Corre R; Greillier L; Le Caër H; Audigier-Valette C; Baize N; Bérard H; Falchero L; Monnet I; Dansin E; Vergnenègre A; Marcq M; Decroisette C; Auliac JB; Bota S; Lamy R; Massuti B; Dujon C; Pérol M; Daurès JP; Descourt R; Léna H; Plassot C; Chouaïd C
    J Clin Oncol; 2016 May; 34(13):1476-83. PubMed ID: 26884557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
    Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
    Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P;
    Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
    Ahn HK; Jung M; Sym SJ; Shin DB; Kang SM; Kyung SY; Park JW; Jeong SH; Cho EK
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):277-82. PubMed ID: 24906423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
    Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
    Shi X; Yu XM; Zhang YP; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
    Georgoulias V; Samonis G; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Grigoratou T; Palamidas P; Kouroussis C; Mavroudis D; Kakolyris S; Giannakakis T; Vlachonikolis J;
    Lung Cancer; 2001 Dec; 34 Suppl 4():S47-51. PubMed ID: 11742702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
    Karampeazis A; Vamvakas L; Kotsakis A; Christophyllakis C; Kentepozidis N; Chandrinos V; Agelidou A; Polyzos A; Tsiafaki X; Hatzidaki D; Georgoulias V
    J Geriatr Oncol; 2017 Jan; 8(1):23-30. PubMed ID: 27264267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Matano E; Boni C; Marangolo M; Failla G; Altavilla G; Adamo V; Ceribelli A; Clerici M; Di Costanzo F; Frontini L; Tonato M;
    J Clin Oncol; 2002 Nov; 20(21):4285-91. PubMed ID: 12409326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.